- KKR and OMX Ventures lead $55 million seed funding round
- Replay’s genomic medicine toolkit encompasses a portfolio of disruptive platform technologies to write and deliver big DNA, including a high payload capacity HSV delivery platform, a hypoimmunogenic cell therapy platform, and a proprietary genome writing platform
- Company is led and supported by a world-class team of academics, entrepreneurs, and industry experts
- Innovative hub-and-spoke business model separates technology development from product development, leveraging Replay’s technologies within discrete product companies
- Five product companies have been incorporated to date
San Diego, California and London, UK, 25 July 2022 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced its launch with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial.